GSK plc (GSK) ORD GBP0.3125
- Add to watchlist
- Create an alert
- This stock can be held in a
1,325.00p
1,357.58p
1,820.00p
£54.76 bn
1,309.50p
1,319.50p
1,282.50p
8.44
9.50p (0.73%) Previous:
9.50p
7,504,795
4.32%
1,500
Performance
1 week 1W | 3.15% | 1 year 1Y | 4.9% |
---|---|---|---|
1 month 1M | 7.67% | 2 years 2Y | 4.8% |
3 months 3M | 15.97% | 3 years 3Y | 14.05% |
6 months 6M | 24.97% | 5 years 5Y | 23.46% |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
Fundamental data
Year ending: | 31/12/2023 | 31/12/2022 |
---|---|---|
Revenue (£m) | 30,328.00 | 29,324.00 |
Profit before tax (£m) | 6,064.00 | 5,628.00 |
Adjusted EPS (p): | 155.10 | 139.70 |
P/E ratio | 9.40 | 10.30 |
PEG | 0.90 | 0.20 |
EPS growth (%) | 11.00 | 54.00 |
Values are quoted in the stock's local currency: British pound
All fundamental dataRecent dividends paid or declared by GSK plc:
Type | Ex-div date | Payment date | Amount |
---|---|---|---|
Q3 * | 15/11/2024 | 09/01/2025 | 15.00p |
Q2 | 15/08/2024 | 10/10/2024 | 15.00p |
Q1 | 16/05/2024 | 11/07/2024 | 15.00p |
Q4 | 22/02/2024 | 11/04/2024 | 16.00p |
Q3 | 16/11/2023 | 11/01/2024 | 14.00p |
* Dividend has not yet been paid but has been declared by GSK plc.
This data is provided by Digital Look. HL accepts no responsibility for its accuracy and you should independently check data before making any investment decision.
Full dividend historyFive years' total annual GSK plc dividends:
Financial year end |
Dividend yield |
Dividend cover |
Total dividend paid |
---|---|---|---|
31/12/2023 | 2.90% | 3.69 | 58.00p |
31/12/2022 | 3.10% | 3.17 | 57.75p |
31/12/2021 | 4.00% | 1.13 | 80.00p |
31/12/2020 | 4.80% | 1.45 | 80.00p |
31/12/2019 | 3.60% | 1.55 | 80.00p |
All dividend data is calculated excluding any special dividends. Historical dividends may be adjusted to reflect any subsequent rights issues and corporate actions.
Full dividend historyReady to invest?
Important Documents
There are no documents available for this stock.
-
GSK's Arexvy approved for wider age range in Japan
22 November 2024 07:17
-
GSK's linerixibat meets primary endpoint
19 November 2024 09:21
-
London close: Stocks end turbulent week in the red
15 November 2024 15:21
-
Japan approves first RSV vaccine for adults 50-59
22 November 2024 07:00
-
Director/PDMR Shareholding
19 November 2024 15:30
-
GLISTEN Trial of Linerixibat Meets Endpoint
19 November 2024 07:00
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.